Tirzepatide is approved for obstructive sleep apnea with obesity, and the obvious next question is whether it works as well for everyone. Post hoc analyses of the two trials behind that approval cut the results by age, sex, BMI, starting severity and neck circumference[1]. What the trial measured in the first place is set out in tirzepatide and sleep apnea.
The broad answer is yes. Reductions in the apnea-hypopnea index appeared in every subgroup examined, alongside improvements in body weight, systolic blood pressure and the sleep-apnea-specific hypoxic burden, which measures how much oxygen desaturation someone actually accumulates rather than just counting events.
That matters for anyone converting a trial number into an expectation. A person with an AHI of 18 and a person with an AHI of 60 will both improve on this evidence, and they will not improve by the same amount, and the average reported for the trial describes neither of them. It is the same reason a percentage weight loss from a lighter starting population is not comparable to one from a heavier one, as the ecnoglutide trial illustrates.
The word to hold onto is the authors’ own: descriptive. No interaction tests are reported here and no confidence intervals accompany the subgroup estimates, so “consistent across subgroups” means the ranges overlap rather than that heterogeneity was tested and ruled out. That is a weaker statement than the prespecified sex analysis in the HFpEF trial, where interaction P values were calculated and reported.
None of this touches the question that follows from a good result, which is what happens to the machine beside the bed. Improving on a measurement is not the same as no longer needing treatment, and a sleep study is the only thing that establishes the difference — a practice gap covered in the cardiac imaging evidence from a different direction.